Literature DB >> 22221825

Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells.

Xue-Wei Yang1, Xiao-Li Wang, Liang-Qi Cao, Xiao-Feng Jiang, He-Ping Peng, Shao-Mang Lin, Ping Xue, De Chen.   

Abstract

AIM: 5-Fluorouracil (5-FU) is one of the most commonly used chemotherapeutic drugs. Resistance to 5-FU is a major cause of chemotherapy failure in advanced-stage hepatocellular carcinoma (HCC). Green tea polyphenol Epigallocatechin-3-gallate (EGCG) plays a critical role in growth inhibition and apoptotic induction in HCC cell lines. The aim of this study is to investigate whether EGCG can enhance 5-FU-induced cell growth inhibition and to explore its potential mechanisms.
METHODS: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to evaluate cell growth. Western blotting analysis was performed to detect the proteins expression in Hep3B cells. Small interfering RNA was used to suppress cyclooxygenase-2 (COX-2) expression. Furthermore, enzyme linked immunosorbent assay was used to test the prostaglandin E(2) (PGE(2) ) production in cell cultures.
RESULTS: Epigallocatechin-3-gallate augmented the anti-tumor effect of 5-FU in Hep3B cells. Significant difference was observed between the treated groups and the control group (P < 0.05). EGCG (its concentrations at over 5 µmol/L) combined with 5-FU presented a synergic effect. Furthermore, the combination of EGCG and 5-FU abrogated the COX-2 overexpression and PGE(2) secretion induced by 5-FU. The upregulation of COX-2 expression decreased the phosphorylation of Akt (Thr(308) ) expression. These appeared to be followed by the AMPK hyperactivation.
CONCLUSION: Epigallocatechin-3-gallate sensitizes HCC cells to 5-FU antitumor activity, and the combination of EGCG and 5-FU exhibits synergism in chemo-resistant cancer cells. The results suggest potential novel therapies for the treatment of advanced-stage liver cancer.
© 2012 The Japan Society of Hepatology.

Entities:  

Year:  2012        PMID: 22221825     DOI: 10.1111/j.1872-034X.2011.00947.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  16 in total

Review 1.  Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009 - present).

Authors:  Kristin Landis-Piwowar; Di Chen; Robert Foldes; Tak-Hang Chan; Qing Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2012-12-12       Impact factor: 6.674

Review 2.  Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds.

Authors:  Hirota Fujiki; Eisaburo Sueoka; Tatsuro Watanabe; Masami Suganuma
Journal:  J Cancer Res Clin Oncol       Date:  2014-12-28       Impact factor: 4.553

3.  Organotypic culture of breast tumor explants as a multicellular system for the screening of natural compounds with antineoplastic potential.

Authors:  Irma Edith Carranza-Torres; Nancy Elena Guzmán-Delgado; Consuelo Coronado-Martínez; José Inocente Bañuelos-García; Ezequiel Viveros-Valdez; Javier Morán-Martínez; Pilar Carranza-Rosales
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

4.  Reversal of Cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells.

Authors:  Kyung-Chan Kim; Chuhee Lee
Journal:  Korean J Physiol Pharmacol       Date:  2014-02-13       Impact factor: 2.016

5.  Epigallocatechin-3-gallate enhances the therapeutic effects of leptomycin B on human lung cancer a549 cells.

Authors:  Meghan M Cromie; Weimin Gao
Journal:  Oxid Med Cell Longev       Date:  2015-04-01       Impact factor: 6.543

6.  Reduction in promotor methylation utilizing EGCG (epigallocatechin-3-gallate) restores RXRα expression in human colon cancer cells.

Authors:  Jay Morris; Vondina R Moseley; April B Cabang; Katie Coleman; Wei Wei; Elizabeth Garrett-Mayer; Michael J Wargovich
Journal:  Oncotarget       Date:  2016-06-07

7.  Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil.

Authors:  Jung Ho Han; MinJeong Kim; Hyeon Jin Kim; Se Bok Jang; Sung-Jin Bae; In-Kyu Lee; Dongryeol Ryu; Ki-Tae Ha
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

8.  Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy.

Authors:  Inyoung Kim; Yu-Ying He
Journal:  Front Oncol       Date:  2013-07-15       Impact factor: 6.244

9.  The Epidemiological Investigation on the Risk Factors of Hepatocellular Carcinoma: A Case-Control Study in Southeast China.

Authors:  Jianjun Niu; Yong Lin; Zhinan Guo; Mu Niu; Chenghao Su
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

10.  Upregulation of Akt/NF-κB-regulated inflammation and Akt/Bad-related apoptosis signaling pathway involved in hepatic carcinoma process: suppression by carnosic acid nanoparticle.

Authors:  Bo Tang; Fang Tang; Zhenran Wang; Guangying Qi; Xingsi Liang; Bo Li; Shengguang Yuan; Jie Liu; Shuiping Yu; Songqing He
Journal:  Int J Nanomedicine       Date:  2016-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.